Skip to content
The Nexus
DossierENTITY

Valneva

Coverage of Valneva in the Nexus archive.

Earliest in view: Jun 30 · 09:00 UTCMost recent: Jul 6 · 23:57 UTC
Co-mentioned in this coverage
University of Bergenorganization1Norwegian Research Centerorganization1enterotoxigenic Escherichia colitopic1James Fleckensteinperson1Washington University School of Medicine in St. Louisorganization1Pfizerorganization1Lyme diseasetopic1KFF Health Newsorganization1Jess Manganelliperson1Theodore Roosevelt Conservation Partnershiporganization1Centers for Disease Control and Preventionorganization1
Recent coverage
  • HEALTHJul 6 · 23:57 UTCFOX NEWS
    Experimental vaccine shows promise against dangerous intestinal illness

    An experimental vaccine targeting enterotoxigenic Escherichia coli (ETEC), a major cause of severe diarrhea, has reached a development milestone and was licensed to Valneva. Researchers at the University of Bergen and Norwegian Research Center (NORCE) developed the technology, which shows promise in eliciting protective immune responses in children. The vaccine remains in development, requiring further trials and regulatory approval before public availability.

  • HEALTHJun 30 · 09:00 UTCKFF HEALTH NEWS
    Would Hunters Take a Lyme Disease Vaccine? We Asked

    Pfizer and Valneva plan to seek approval for a new Lyme disease vaccine, following the failure of a 1990s vaccine due to lawsuits and public fear. A survey of hunters, a high-risk group for tick exposure, found mixed reactions, with some expressing interest and others seeking more information about safety and effectiveness.